Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-RM2 and 68Ga-PSMA-11 PET/MRI in Prostate Cancer
NCT04264208Phase 2Terminated
- Sponsor
- Andrei Iagaru
- Start
- Feb 2020
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Andrei Iagaru. Primary endpoints: Number of Participants With Successful Assessment of PET Based PC Lesions at 2 weeks, Number of Participants for Which an Assessment of PET Based Therapeutic Response to HDR is Successfully Obtained at 2 weeks and 1 more. Started Feb 2020; status: terminated.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04264208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264208.